The ides of March come for Immutep as lung cancer trial cancellation triggers plummet

The Market Herald

Mar 13

Immutep Ltd (ASX:IMM) has seen its share price slaughtered on Friday after it’s effectively ditched its lead candidate for the treatment of lung cancer, a move that spells doom for any biotech – the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2619152346"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619152346\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619152346?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 10:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619152346","market":"nz","top_or_hot":-1,"title":"The ides of March come for Immutep as lung cancer trial cancellation triggers plummet","media":"The Market Herald","content":"<div>\n<p>Immutep Ltd (ASX:IMM) has seen its share price slaughtered on Friday after it’s effectively ditched its lead candidate for the treatment of lung cancer, a move that spells doom for any biotech – the ...</p>\n\n<a href=\"https://themarketonline.com.au/the-ides-of-march-come-for-immutep-as-lung-cancer-trial-cancellation-triggers-plummet-2026-03-13/\">Source Link</a>\n\n</div>\n","source":"markerherald_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The ides of March come for Immutep as lung cancer trial cancellation triggers plummet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe ides of March come for Immutep as lung cancer trial cancellation triggers plummet\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-13 10:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://themarketonline.com.au/the-ides-of-march-come-for-immutep-as-lung-cancer-trial-cancellation-triggers-plummet-2026-03-13/><strong>The Market Herald</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Immutep Ltd (ASX:IMM) has seen its share price slaughtered on Friday after it’s effectively ditched its lead candidate for the treatment of lung cancer, a move that spells doom for any biotech – the ...</p>\n\n<a href=\"https://themarketonline.com.au/the-ides-of-march-come-for-immutep-as-lung-cancer-trial-cancellation-triggers-plummet-2026-03-13/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://themarketonline.com.au/the-ides-of-march-come-for-immutep-as-lung-cancer-trial-cancellation-triggers-plummet-2026-03-13/","article_id":"2619152346","we_media_id":null,"thumbnails":[],"rights":{"source":"markerherald_stock","url":"https://themarketonline.com.au/the-ides-of-march-come-for-immutep-as-lung-cancer-trial-cancellation-triggers-plummet-2026-03-13/","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619152346","pubTimestamp":1773369840,"columns":[],"sourceInfo":{"source_id":"markerherald_stock","name":"The Market Herald"},"weMediaInfo":null,"summary":"Immutep Ltd  has seen its share price slaughtered on Friday after it’s effectively ditched its lead candidate for the treatment of lung cancer, a move that spells doom for any biotech – the speculative trader’s speculative investment class of choice.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week.On Spotify, Apple, and more.Cue Immutep sinking -88% in one intraday session – in fact, out the gate – down to 4.6cps. The stock closed at 40cps on Thursday – bringing Immutep’s YTD performance down negative -88%; its market cap to $68M, and its average liquidity to a more respectable level.if $11M feels low, note the company has 1.5B shares on issue. Still, for biotechs, that isn’t necessarily unusual –it’s a long hard road out of hell and to TGA  approval.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research a","collect":0,"end_time":0,"defaultTopTitle":"themarketonline.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","IMM.AU":"IMMUTEP LTD","BK7067":"生物科技"},"translate_title":"随着肺癌试验取消触发因素直线下降，Immutep的三月十五日即将到来","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMM.AU":1},"content_text":"Immutep Ltd (ASX:IMM) has seen its share price slaughtered on Friday after it’s effectively ditched its lead candidate for the treatment of lung cancer, a move that spells doom for any biotech – the speculative trader’s speculative investment class of choice. \nListen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.\nCue Immutep sinking -88% in one intraday session – in fact, out the gate – down to 4.6cps. The stock closed at 40cps on Thursday – bringing Immutep’s YTD performance down negative -88%; its market cap to $68M, and its average liquidity to a more respectable level. \nA shame that it’s all flowing out in the wrong direction. Immutep has been a fairly quiet stock of late, but on Friday, as at 1.20PM SYD, 332.4M shares had traded hands for a total of $11.5M versus a 4Wavg of a mere 1.8M shares. \nif $11M feels low, note the company has 1.5B shares on issue. Still, for biotechs, that isn’t necessarily unusual – it’s a long hard road out of hell and to TGA (or FDA) approval.\n“Based on its review of the available safety and efficacy data, the [reviewing committee[ recommended that the trial be discontinued for futility,” Immutep wrote pre-market on Friday of its ongoing trial using flagship candidate TACTI-004. \nThe big kicker is that this was a Phase III trial – the be-all-or-end-all of developmental drug ambitions – and so investors have withdrawn cash instead of waiting to see if the company can eke a recovery out of stone. \nBecause that will take at least half a decade – around the same time those suffering from lung cancer may have to live. \nIMM last traded at 4.6cps. \nJoin the discussion: See what HotCopper users are saying about IMM and be part of the conversations that move the markets.\nThe material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}